Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 master protocol of setmelanotide versus placebo in obesity due to MC4R-pathway genetic variants
MOH_2022-08-30_010780Phase 3Not yet recruiting
- Sponsor
- Rhythm Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in monogenic obesity comparing Setmelanotide with Matching placebo (2 arms). Primary endpoints: Proportion of responders at Week 52 and Comparison of responder proportion between active treatment and placebo. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
setmelanotide
03
Conditions
monogenic obesity
Beyond the preview
Go deeper on MOH_2022-08-30_010780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-30_010780.